Speaker

Richard S Finn, MD

Richard S Finn, MD

Biography

Richard S. Finn, MD
Professor
Department of Medicine
Division of Hematology/ Oncology
UCLA David Geffen School of Medicine
Medical Director, Clinical Research Unit
Director, Signal Transduction and Therapeutics Program,
Jonsson Comprehensive Cancer Center
University of California, Los Angeles

Dr Finn is a Professor of Clinical Medicine in the Division of Hematology/ Oncology at the UCLA David Geffen School of Medicine and Medical Director of the Clinical Research Unit and Director of the Signal Transduction Program in the Jonsson Comprehensive Cancer Center at UCLA.

He currently splits his time between patient care and laboratory and clinical research. His research interests lie in the development of molecular targeted agents and biomarkers in liver cancer and breast cancer. Dr Finn has served as principal and sub-investigator in trials exploring the use of targeted therapies in breast and hepatobiliary cancers. He has a particular interest in identifying predictive markers of response to novel therapeutics. His work has been published in journals such as the New England Journal of Medicine, The Lancet, Journal of Clinical Oncology, Lancet Oncology, Cancer Research, Clinical Cancer Research, Hepatology, Cancer Cell, Nature Medicine, and elsewhere. Dr Finn has also given oral presentations at major meetings including American Society of Clinical Oncology (ASCO), European Cancer Conference (ECCO/ ESMO), and the American Association of Cancer Research (AACR), International Liver Cancer Association (ILCA), and others. An active cancer researcher, he has been involved in the development of several novel therapeutics in cancer medicine. He has brought several practice changing advances to cancer medicine. He played a lead role in the approval of palbociclib (Ibrance), the first CDK 4/6 inhibitor in cancer medicine, from pre-clinical development to global registration and more recently the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) for the treatment of advanced liver cancer.

Dr Finn is a member of ASCO, American Association of Cancer Research (AACR) and the European Society of Medical Oncology (ESMO). He is a past president of the International Liver Cancer Association (ILCA). He is on the editorial board of Clinical Cancer Research, Breast Cancer Research, and Hepatology Communications

Sessions

8:00 AM - 5:30 PM
Nov 15 2024
San Diego, CA

Postgraduate Course, Parts 1-4: The Future Is Here - Practicing Hepatology in 2024 (Ticketed)

David E Kaplan, MD, MS, MSc, FAASLD, FACP, AGAF, Presenter
Pichamol Jirapinyo, MD, Presenter
Mazen Noureddin, MD, MHSc, Presenter
Ponni V. Perumalswami, MD, FAASLD, Presenter
George N. Ioannou, MD, FAASLD, Presenter
Julie Heimbach, MD, FAASLD, Presenter
Richard S Finn, MD, Presenter
Laura M Kulik, MD, Presenter
Neil Mehta, MD, Presenter
Paul Y Kwo, MD, FAASLD, Presenter
Binita M Kamath, MBBChir, FAASLD, Presenter
Therese Bittermann, MD, Presenter
Jordan J. Feld, MD, MPH, FAASLD, Presenter
Ashley Spann, MD, MSACI, Presenter
Salvatore Piano, MD, Presenter
David P Foley, MD, FACS, FAST, FAASLD, Presenter
Vijay H. Shah, MD, FAASLD, Presenter
Acute Liver Failure
Acute-on-Chronic Liver Failure
ALD
Basic Science
Cirrhosis and Portal Hypertension
DEI
Drug-Induced Liver Injury
Hepatitis
Hepatology Associates
Liver Cancer
MASLD
Pediatrics
Trainee
Transplant
7:30 PM - 9:30 PM
Nov 16 2024
San Diego, CA

LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today, and Tomorrow?